Univercells and NIBRT Team Up to Address Needs for Cell and Gene Therapy Training

Univercells Technologies and the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, announced on May 18, 2021 that they have entered into a collaboration to address the need for training in cell and gene therapies (CGTs) using next-generation technologies for viral products manufacture.

Through the partnership, Univercells will introduce the intermediate capacity scale-X carbo system, which includes a fixed-bed bioreactor and in-line concentration, to NIBRT’s facility for hands-on demonstration and training to enforce continued education and bridge the clinical gap between new CGT manufacturing staff and expert level biopharmaceutical professionals, Univercells said in a company press release.

“Across the industry, developers and manufacturers are looking for next generation technologies. They require purposefully designed tools that apply the principles of intensification, integration, and semi- or fully continuous processing to overcome the existing barriers to discovery and commercialization in viral manufacturing,” said CEO of Univercells Technologies, Mathias Garny, in the press release. “Our scale-X product series is a uniquely intensified and automated solution that can help to bring advanced therapies to the market using reliable, reproducible processes with increased capacity in a decreased footprint. We are honored to have it featured at a respected institute like NIBRT and contribute to training the workforce that will drive manufacture of the advance therapies of tomorrow.”

“We are always looking out for the latest bioprocessing innovations to accomplish our mission of supporting the biopharmaceutical industry with access to the most advanced technologies for research and training,” added John Milne, NIBRT training director, in the press release. “The scale-X carbo system is the ideal intermediate-scale system to train on process development, optimization, and scale-up principles through R&D to commercial capacity. The scale-X carbo system will help our team to deliver cutting edge training and research collaborations in viral vector development.”

Source: Univercells